Drexel scientist refutes Trump’s claim linking Tylenol to autism, stating there is no evidence supporting the connection.

Drexel University researcher Brian Lee has undertaken one of the most extensive investigations to date regarding the safety of Tylenol, or acetaminophen, during pregnancy. His comprehensive study, published in the esteemed medical journal JAMA last year, revealed no correlation between the use of Tylenol by pregnant mothers and the subsequent development of autism in their children. This finding aligns with established medical guidelines that have long suggested Tylenol as a safe option for expectant mothers dealing with pain or fever, conditions that can pose significant risks during pregnancy.

Opinions have diverged sharply on this issue, notably highlighted by remarks from former President Donald Trump, who asserted during a White House news briefing that using acetaminophen during pregnancy may pose dangers to the fetus. He characterized his comments as a significant medical pronouncement.

In a separate initiative, the Trump administration announced that the Food and Drug Administration would permit the use of leucovorin, a generic folate medication, for children with autism. This announcement was made in a press conference that included figures such as Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary.

For more than a decade, researchers have sought to understand the potential links between acetaminophen use and autism. While no definitive evidence has substantiated claims that the painkiller causes autism, some studies have identified a statistical association. However, Lee’s research analyzed data from 2.5 million mothers and their children in Sweden over two decades. Though a slight statistical correlation was noted, Lee emphasized that correlation does not imply causation.

To further investigate this association, Lee employed a sibling analysis, comparing outcomes between siblings born to the same parents. This approach effectively accounted for genetic factors, which are known to be major contributors to autism risk. The findings indicated no association between acetaminophen use and autism when genetic risk factors were considered.

The difficulty in establishing a direct causal relationship stems from the lack of randomized controlled trials, which are considered the gold standard for determining causation. Observational studies that do not account for genetic influences often yield weaker results, an issue highlighted by Lee.

The Trump administration has also proposed the launch of a million Autism Data Science Initiative aimed at examining the underlying causes of autism, emphasizing the importance of identifying environmental toxins. However, experts like Matthew Lerner from Drexel University stress that genetics play a dominant role in autism risk, indicating the condition’s inheritability is comparable to height.

As the discussion surrounding acetaminophen and autism continues, medical associations have reaffirmed that prudent use of acetaminophen during pregnancy does not present clear evidence of fetal developmental issues. The American College of Obstetricians and Gynecologists has reiterated its guidance, asserting the safety of acetaminophen during pregnancy.

Despite these reassurances, Trump’s recommendations against acetaminophen could create confusion for expectant mothers, potentially leading to dangerous consequences such as untreated fevers. Medical experts emphasize the importance of addressing fevers during early pregnancy to reduce risks of deficiencies in the developing infant.

This divergence between expert consensus and public messaging from high-profile figures could pose challenges for pregnant individuals seeking reliable health advice. The discourse highlights a critical need for clear, evidence-based guidance in addressing maternal health concerns during pregnancy.